During this time, the number of NextBio users at Burnham has nearly doubled, and that number continues to grow. We are enthusiastic about the upcoming product releases.
CUPERTINO, Calif. (PRWEB) October 2, 2008
"NextBio was extremely helpful when it came time to interpret and publish our research findings," stated Huichun Xu, MD, at the MIND Institute and Department of Neurology at the University of California at Davis. "We uploaded results that our lab generated while studying different types of stroke. In a matter of minutes, literally, we were comparing our data to gene signatures from thousands of other experiments, collected from many data sources. The sheer content available at your fingertips is amazing. Searching for this information without NextBio would have been a huge project in and of itself."
"Researchers at the Burnham Institute for Medical Research have been using NextBio for over a year to better understand and combine public life sciences research with our internal data," stated Alexey Eroshkin, Ph.D., from the Burnham Institute for Medical Research. "During this time, the number of NextBio users at Burnham has nearly doubled, and that number continues to grow. We are enthusiastic about the upcoming product releases."
"We have seen an explosion in the traffic on our public search engine," said Saeid Akhtari, co-founder and CEO of NextBio. "While we continue to see strong traction among our paying pharmaceutical, academic and biotech customers for the enterprise version of our product, which includes advanced security and analytical features, the viral growth of our public site has exceeded all expectations. We are gratified that scientists all across the world are using NextBio to make new breakthrough discoveries."
As NextBio continues to innovate its search engine, add new enterprise features and enhance its free community and collaboration offerings, its popularity has grown to make it the number one destination for the life sciences community for search and collaboration.
NextBio is a privately held, venture-backed company that provides an innovative search engine specifically for the life science community. NextBio provides instant access and search, user-generated content and collaboration to scientists and clinicians worldwide, enabling them to access and understand the world's life sciences information to find important new correlations, make discoveries and generate hypotheses as never before. NextBio is implemented via a Software-as-a-Service (SaaS) model that enables users to search directly or via internal company sites through the NextBio Application Programming Interface (API). The enterprise version of the NextBio search engine is being used in life science R&D and drug development by researchers and clinicians at Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Celgene, Genzyme, Eli Lilly and Company, and Regeneron Pharmaceuticals, among others. For more information on the company, please visit our website at http://www.nextbio.com.